AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; 27 of the 44 sources its claims cite were checked for support.
Abstract
Background: The maintenance of complex dendritic arbors and synaptic transmission are processes that require a substantial amount of energy. Bioenergetic decline is a prominent feature of chronic neurodegenerative diseases, yet the signaling mechanisms that link energy stress with neuronal dysfunction are poorly understood. Recent work has implicated energy deficits in glaucoma, and retinal ganglion cell (RGC) dendritic pathology and synapse disassembly are key features of ocular hypertension damage. Results: We show that adenosine monophosphate-activated protein kinase (AMPK), a conserved energy biosensor, is strongly activated in RGC from mice with ocular hypertension and patients with primary open angle glaucoma. Our data demonstrate that AMPK triggers RGC dendrite retraction and synapse elimination. We show that the harmful effect of AMPK is exerted through inhibition of the mammalian target of rapamycin complex 1 (mTORC1). Attenuation of AMPK activity restores mTORC1 function and rescues dendrites and synaptic contacts. Strikingly, AMPK depletion promotes recovery of light-evoked retinal responses, improves axonal transport, and extends RGC survival. Conclusions: This study identifies AMPK as a critical nexus between bioenergetic decline and RGC dysfunction during pressure-induced stress, and highlights the importance of targeting energy homeostasis in glaucoma and other neurodegenerative diseases.
Overview
CoChat Summary
TL;DR
AMPK is hyperactivated in retinal ganglion cells (RGCs) after ocular hypertension in mice and in primary open-angle glaucoma patient retinas, and this activation drives dendrite retraction and synapse loss. Attenuating AMPK restores mTORC1 signaling, rescues dendrites and synapses, improves light-evoked retinal responses and axonal transport, and extends RGC survival.
Key findings
- At 2 weeks after microbead-induced ocular hypertension, RGC dendritic area, length, and branch number decreased by 22%, 28%, and 24%, respectively, and pre-/postsynaptic VGLUT1–PSD95 colocalized voxels in the inner plexiform layer decreased by 65%.
- Active AMPK (pAMPKThr172) increased in RGCs from ocular hypertensive mice as early as 1 week and was also elevated in RGCs from primary open-angle glaucoma patients, with a reported two-fold increase in pAMPKThr172-positive RGC epifluorescence versus age-matched controls.
- AMPK knockdown with siAMPK protected dendritic field area (90%), length (86%), and branches (93%) versus siCTL (area 62%, length 66%, branches 80%), and rescued VGLUT1/PSD95 synaptic voxels; co-administration of rapamycin blocked these dendritic and synaptic rescues.
- siAMPK improved RGC function and survival: pSTR amplitude was preserved, anterograde CTB transport was 93% versus 62% in controls, RGC soma survival was 93% versus 75%, and optic nerve axon survival was 98% versus 78%.
Methods
- Unilateral ocular hypertension was induced in female Thy1-YFPH or wild-type littermate mice (3–4 months old) by magnetic microbead injection into the anterior chamber; intraocular pressure was measured biweekly, and sham controls received PBS.
- Human retinas were obtained from 27 primary open-angle glaucoma surgical specimens and 15 age-matched controls; RGCs were identified with Brn3a or RBPMS and analyzed for pAMPKThr172 by immunohistochemistry.
- Interventions included intraperitoneal compound C or rapamycin and intravitreal siAMPK or control siRNA; outcomes included dendritic arbor reconstruction, synaptic marker voxel analysis, western blot, qPCR, ERG pSTR, CTB axonal transport, and RGC soma/axon counts, analyzed by ANOVA with Tukey’s post hoc test or Student’s t-test.
Limitations
- The paper states that complete AMPK inhibition can be detrimental, that the siRNA approach conferred only partial AMPK inhibition, and that the timing and duration of AMPK modulation are critical; it also notes that rapamycin can have non-specific or off-target effects and that a narrow 2-week therapeutic window was used.
- Evident from the text: the mechanistic evidence comes mainly from a mouse microbead ocular hypertension model, with human data limited to postmortem/surgical POAG specimens and no direct human intervention; mouse experiments used female mice only.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
20 Valid · 1 Not valid · 6 Not checked · 94 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Co-administration of siAMPK and rapamycin, an inhibitor of mTORC1 [30], blocked the effect of siAMPK on dendritic and synaptic rescue (Fig. 4I-Q)”
§ AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma > Results > AMPK knockdown rescues RGC dendrites and synapses through mTORC1 activation
What the sources say
- Could not verifycites [30] Mansour-Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo AJ. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci U S A. 1994;91(5):1632–6. https://doi.org/10.1073/pnas.91.5.1632. sourceExperimental — accuracy not yet measured
The citation is attached to the description of rapamycin as an mTORC1 inhibitor, while the rescue result is attributed to Fig. 4I–Q. The cited paper’s Materials and Methods and Results describe BDNF injections and retinal ganglion cell survival and regrowth; searches for rapamycin, mTORC1, siAMPK, and dendritic or synaptic rescue found no passage addressing the cited description or the rescue result. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Specifically, compensatory pathways are activated in response to chronic rapamycin treatment [66, 67].”
§ AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma > Discussion
What the sources say
- Partly supportedcites [66] Fang Y, Westbrook R, Hill C, Boparai RK, Arum O, Spong A, et al. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab. 2013;17(3):456–62. https://doi.org/10.1016/j.cmet.2013.02.008. sourceExperimental — accuracy not yet measured
The Results section (“Both mTORC1 and mTORC2 were Involved in Metabolic Alterations”; page not available) reports that 20 weeks of rapamycin reversed several signaling responses seen after shorter treatment. The Discussion says prolonged treatment no longer inhibited phosphorylation of several signaling proteins, but explicitly leaves the mechanism unclear; it does not establish that compensatory pathways were activated. (LLM, conf=0.83)
- Supportedcites [67] Houde VP, Brûlé S, Festuccia WT, Blanchard P-G, Bellmann K, Deshaies Y, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes. 2010;59(6):1338–48. https://doi.org/10.2337/db09-1324. source
The Results section (page not provided) reports that in adipose tissue of rapamycin-treated rats, increased Akt activity and Thr308 phosphorylation more than compensated for reduced Ser473 phosphorylation. The paper also reports activation of hepatic gluconeogenic regulators after chronic treatment, supporting the broad statement that compensatory pathways are activated. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We previously showed that mTORC1 is essential for RGC dendritic maintenance and regeneration [34, 46].”
§ AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma > Discussion
What the sources say
- Partly supportedcites [34] Morquette B, Morquette P, Agostinone J, Feinstein E, McKinney RA, Kolta A, et al. REDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury. Cell Death Differ. 2015;22(4):612–25. https://doi.org/10.1038/cdd.2014.149. sourceExperimental — accuracy not yet measured
The Discussion (page not available) says mTORC1 is required for the stability of adult RGC dendrites, supporting dendritic maintenance. It discusses mTOR’s role in RGC axon regeneration, but describes mTORC1’s contribution to regeneration as possible rather than establishing that it is essential. (LLM, conf=0.88)
- Partly supportedcites [46] Agostinone J, Alarcon-Martinez L, Gamlin C, Yu W-Q, Wong ROL, Di Polo A. Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury. Brain. 2018;141(7):1963–80. https://doi.org/10.1093/brain/awy142. sourceExperimental — accuracy not yet measured
The Results section (‘mTORC1 is required for insulin-mediated dendritic branching and restores arbour complexity’; page unavailable) shows that mTORC1 knockdown reduced regenerating branches in injured RGCs. It also reports that the same knockdown did not change dendritic parameters in non-injured retinas, so this paper does not establish that mTORC1 is essential for dendritic maintenance. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The predicted energy expenditure at dendrites is substantial [1], consistent with the high density of mitochondria and oxidative activity found in the dendritic compartment [2].”
§ AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma > Background
What the sources say
- Supportedcites [1] Harris JJ, Jolivet R, Attwell D. Synaptic energy use and supply. Neuron. 2012;75(5):762-77. https://doi.org/10.1016/j.neuron.2012.08.019. source
The passage discussing Figures 2B–C (indexed as Abstract; no page supplied) says that reversing ion movements from postsynaptic responses consumes the great majority of energy used at excitatory synapses, and compares predicted expenditure in dendrites and soma with other compartments. That supports the claim of substantial predicted dendritic energy expenditure. The mitochondria and oxidative-activity clause is attributed to [2], not this source. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Recent work has strongly implicated energy deficits in glaucoma [18–23], and reduced AMPK correlates with anti-inflammatory responses and RGC protection [24].”
§ AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma > Background
What the sources say
- Not checked — no full text of the sourcecites [18] Chrysostomou V, Rezania F, Trounce IA, Crowston JG. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol. 2013;13(1):12–5. https://doi.org/10.1016/j.coph.2012.09.008. source
- Supportedcites [19] Inman DM, Harun-Or-Rashid M. Metabolic vulnerability in the neurodegenerative disease glaucoma. Front Neurosci. 2017;11:146. source
The “Metabolic vulnerability in glaucoma” section describes emerging evidence for a critical role of energy management in glaucomatous axon degeneration. It also reports depleted ATP and reduced energy reserves in a mouse model of glaucoma. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [20] Nakazawa T. Ocular blood flow and influencing factors for glaucoma. Asia Pac J Ophthalmol. 2016;5(1):38–44. https://doi.org/10.1097/APO.0000000000000183. source
- Not checked — no full text of the sourcecites [21] Osborne NN, Núñez-Álvarez C, Joglar B, del Olmo-Aguado S. Glaucoma: focus on mitochondria in relation to pathogenesis and neuroprotection. Eur J Pharmacol. 2016;787:127–33. https://doi.org/10.1016/j.ejphar.2016.04.032. source
- Supportedcites [22] Williams P, Harder J, John SWM. Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma. J Glaucoma. 2017;26(12):1161–8. https://doi.org/10.1097/IJG.0000000000000767. source
In “Glaucoma, mitochondrial dysfunction, and nicotinamide treatment” (page not available), the paper reports metabolic dysfunction and mitochondrial abnormalities before neurodegeneration in a mouse model of glaucoma, alongside an age-dependent decline in retinal NAD. “Mitochondria and human glaucoma” (page not available) also describes reduced mitochondrial energy production in cells from glaucoma patients and discusses the resulting risk of an energetic crisis. (LLM, conf=0.92)
- Supportedcites [23] Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, et al. Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science (New York, NY). 2017;355(6326):756–60. source
The paper reports early depletion of metabolites needed for mitochondrial metabolism and metabolic stress in retinal ganglion cells during glaucoma. It also concludes that mitochondrial perturbations are among the first changes in those cells. These passages support the broad claim; the indexed copy labels them “Abstract” and provides no page number. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
77 more claims · 2 with their cited sources checked
Create a free account to see all 121 claims and every source verdict.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 19
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subsequently, changes in the expression of autophagy markers were examined 2 weeks after microbead injection, a time that precedes RGC loss and thereby avoids the confounding effect of overt neurodegeneration [58].”
In the citing paper
“This observation is in agreement with previous findings that mTORC1 signaling is partially inactivated in glaucomatous RGCs through AMPK phosphorylation resulting in dendritic retraction [58]”
In the citing paper
“This procedure blocks aqueous humor outflow resulting in elevated intraocular pressure (IOP) (Figure S6 A) [37, 58]”
In the citing paper
“in RGCs, we and others have demonstrated that mTOR inactivation not only regulated autophagy, but also induced neurite shortening during RGC injury, while additional mTOR stimulation can trigger RGC dendrite and axon regeneration [49, 50, 58, 60, 93, 94]”
In the citing paper
“the hypoactivation of mTORC1 and upregulation of AMPK was also identified in the magnetic microbead occlusion mouse glaucoma model [58]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma > Results > Glaucoma-induced energy stress triggers AMPK activation
“Fig. 2O, n = 100 RGC/human retinal specimen, Student’s t-test, p < 0.001, see Methods”
§ AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma > Results > Glaucoma-induced energy stress triggers AMPK activation
“glaucoma: N = 27 retinas/group, n = 100 RGC/group; controls: N = 15 retinas/group, n = 100 RGC/group”
Citations
Cites
Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040
Tham, Y.-C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C.-Y. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.013 · Cited by 7,159
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“To test whether AMPK activation mediates dendritic pathology, we used compound C, a small molecule cellpermeable AMPK blocker [43].”
MethodAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 1×
“AMPK is a potent inhibitor of mTORC1 [45], which we previously showed is a key regulator of RGC dendritic morphology [34, 46].”
BackgroundImaging Neuronal Subsets in Transgenic Mice Expressing Multiple Spectral Variants of GFP
Feng, G., Mellor, R. H., Bernstein, M., Keller-Peck, C., Nguyen, Q. T., Wallace, M., Nerbonne, J. M., Lichtman, J. W., & Sanes, J. R. (2000) · Neuron · doi:10.1016/s0896-6273(00)00084-2 · Cited by 3,042 · cited 1×
“Microbead occlusion was induced in mice expressing yellow fluorescent protein (YFP) under control of the Thy1 promoter (Thy1-YFPH) [33], a transgenic line that allows visualization of individual RGC dendritic trees [34].”
BackgroundSynaptic Energy Use and Supply
Harris, J. J., Jolivet, R., & Attwell, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.019 · Cited by 1,747
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287 · cited 1×
“Rapamycin has been shown to have both beneficial and detrimental effects on metabolism, a disparity that has been largely attributed to non-specific effects depending on the timecourse of administration [64, 65].”
BackgroundHawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D., & Hardie, D. G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27879 · Cited by 1,264 · cited 8×
“When AMP binds to AMPK, it promotes allosteric changes that enhance phosphorylation of threonine 172 (Thr172) on the activation loop of the α subunit by the upstream Liver Kinase B1 (LKB1) [38, 39].”
BackgroundMethodInfluentialCytochrome oxidase: an endogenous metabolic marker for neuronal activity
Wong-Riley, M. T. T. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90165-3 · Cited by 1,238 · cited 1×
“The predicted energy expenditure at dendrites is substantial [1], consistent with the high density of mitochondria and oxidative activity found in the dendritic compartment [2].”
BackgroundRapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934 · cited 1×
“mTORC1 activates the p70-S6 kinase leading to phosphorylation of the ribosomal protein S6 at Ser240/244 residues (pS6) thus stimulating protein translation [47].”
Background
Cited by
Ju, W., Perkins, G. A., Kim, K.-Y., Bastola, T., Choi, W.-Y., & Choi, S. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101136 · Cited by 167
“and enhanced the recovery of light-evoked retinal responses in a mouse model of magnetic microbead-induced occlusion (Belforte et al., 2021).”
Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering
Tribble, J. R., Hui, F., Quintero, H., Hajji, S. E., Bell, K. C., Polo, A. D., & Williams, P. A. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101193 · Cited by 136
Self-citationNeurovascular dysfunction in glaucoma
Alarcón-Martínez, L., Shiga, Y., Villafranca‐Baughman, D., Vargas, J. L. C., Vidal-Paredes, I. A., Quintero, H., Fortune, B. A., Danesh-Meyer, H. V., & Polo, A. D. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101217 · Cited by 95
“Metabolic stress and energy deficits have been shown to contribute to RGC damage in glaucoma (Inman and Harun-Or-Rashid, 2017; Ito and Di Polo, 2017; Morquette and Di Polo, 2008; Williams et al., 2017a; Williams et al., 2017b; Belforte et al., 2021, Quintero et al., 2022).”
BackgroundSelf-citationMitophagy in the retina: Viewing mitochondrial homeostasis through a new lens
Jiménez‐Loygorri, J. I., Benítez‐Fernández, R., Viedma-Poyatos, Á., Zapata‐Muñoz, J., Villarejo‐Zori, B., Gómez‐Sintes, R., & Boya, P. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2023.101205 · Cited by 88
“, 2018), and restoration of mTOR activity protects dendrites in injured RGCs (Belforte et al., 2021).”
McLaughlin, T., Medina, A., Perkins, J., Yera, M., Wang, J. J., & Zhang, S. X. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00528-w · Cited by 84
“A recent study demonstrates that AMPK is activated in RGCs in an ocular hypertension mouse model and in human glaucomatous retina tissue from patients with POAG [69].”
BackgroundInfluential
Metadata
- Authors
- Belforte, N., Agostinone, J., Alarcon-Martinez, L., Villafranca-Baughman, D., Dotigny, F., Cueva Vargas, J. L., & Di Polo, A.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Venue
- Molecular Neurodegeneration
- Published
- 2021-06-29
- Volume
- 16
- Issue
- 1
- Pages
- 43-43
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC8243567
- OpenAlex
- W3174825856
- Semantic Scholar
- ccceb8dc58870465a0b28f8620443bc46ca98686
- Cited by
- 67
- References
- 68
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 13 · 2023: 14 · 2022: 10
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Eye Institute (1R01EY030838-01)
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- AMPK, glaucoma, retinal ganglion cells, dendrite retraction, synaptic loss, mTORC1, ocular hypertension, bioenergetic stress, energy homeostasis, axonal transport, neuronal survival, neurodegeneration
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Adenylate Kinase, Animals, Dendrites, Enzyme Activation, Glaucoma, Open-Angle, Humans, Retinal Ganglion Cells, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma. https://app.cochat.ai/papers/10.1186/s13024-021-00466-z
- The paper
- Belforte, N., Agostinone, J., Alarcon-Martinez, L., Villafranca-Baughman, D., Dotigny, F., Cueva Vargas, J. L., & Di Polo, A. (2021). AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-021-00466-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.